Medical Oncologist
Drug deep dive: Enzalutamide
Enzalutamide Success Rate: — An Honest Look at the Numbers
When your oncologist prescribes enzalutamide, you deserve to understand what the trial data actually shows — and what it cannot tell you. The numbers are real. What they mean for one person takes a conversation.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- The trial data is real — Enzalutamide has shown meaningful improvements in cancer control across several major clinical trials covering different stages of prostate cancer.
- A median is not your number — A median is the midpoint of a group. Half the people in those trials did better than the median — and you could be in that half.
- Multiple measures matter — Success in prostate cancer trials is measured by PSA response, time before disease progresses on scans, and overall survival. Each tells a different part of the story.
- Your stage changes the picture — Enzalutamide is used in different settings. Which trial evidence applies to you depends on where your cancer is now and what treatment you have already had.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Enzalutamide has extended cancer control in major trials for prostate cancer, including AFFIRM, PREVAIL and PROSPER. What those results mean for you specifically depends on your cancer stage, prior treatments, and PSA trends. Your oncologist is the person to interpret your individual situation, because a trial median describes a group, not a prediction for one person.
What does the trial evidence for enzalutamide actually show?
Enzalutamide has been studied in multiple large clinical trials covering different stages of prostate cancer, and NCCN and ESMO include it in their standard recommendations based on that evidence.
In each setting — metastatic castration-resistant disease before and after chemotherapy, and non-metastatic disease at high risk of spreading — the drug showed meaningful improvements compared to placebo on the outcomes the trials measured.
Those outcomes include PSA response, time before cancer progressed on scans, and overall survival. Which trial applies to you depends on where your cancer is now and what treatments you have already had — a question your oncologist will answer directly.
What is a median, and why does it not predict your outcome?
A median is the midpoint of a group: half the people in a trial had a result above it, and half had a result below. It is not an average, and it is not a ceiling on how long a drug can work.
When a trial reports a median time before cancer progressed, roughly half the participants reached that point later than the number stated. Some continued well beyond it. Those people were in the same trial — they just do not appear in the headline figure.
The range of outcomes in any trial is wide, and where you fall within it depends on factors specific to you — your tumour biology, your PSA trend, your overall health. Your oncologist is the person who connects the population data to your individual picture.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What should I ask my oncologist about my results?
- Which trial population am I closest to — pre-chemotherapy, post-chemotherapy, or non-metastatic?
- What are you measuring to judge whether this is working — PSA, scans, or symptoms?
- How often will you check, and what would a meaningful response look like at my first review?
- What would prompt you to consider changing my treatment, and what would the next step be?
- Is there anything in my specific case that affects how I might respond to this drug?
What else should I understand about enzalutamide outcomes?
Is a falling PSA proof that enzalutamide is working?
A falling PSA is a positive signal, and your oncologist will use it as an early indicator of response. But PSA alone is not the complete picture — your team will also look at scan findings and track how you feel. Some patients see PSA change before scans show anything; others the other way around. Your oncologist will tell you what a meaningful response looks like for your specific case and how they plan to monitor it over time.
What happens if my PSA starts rising again while I am taking enzalutamide?
A rising PSA during treatment is a signal worth investigating, but it does not automatically mean the drug has stopped working. Your oncologist will look at how quickly it is rising, whether scans show new activity, and whether you have any new symptoms. PSA movement sometimes runs ahead of scan changes by weeks or months. If a rise is confirmed, your team will discuss whether to continue, adjust, or move to the next line of treatment. There are further options after enzalutamide, and your oncologist will plan ahead for that possibility.
How long does enzalutamide usually work?
The honest answer is that it varies widely, and no figure from a trial can tell you how long it will work in your individual case. In the major trials, the range of outcomes was substantial: some people progressed earlier than the median, and others continued considerably longer. Your oncologist watches whether the cancer is actively growing, not a countdown from a population average. If your PSA is stable or falling and scans are unchanged, the drug is doing what it is meant to do.
Does enzalutamide cure prostate cancer?
In the settings where it is used — castration-resistant prostate cancer and high-risk non-metastatic disease — enzalutamide aims to control the cancer and extend the time before it progresses, not to cure it. NCCN and ESMO recommend it based on evidence built around those control-and-extend goals. This distinction matters: the intent of treatment shapes how you interpret your results, and it is worth asking your oncologist directly if you are uncertain what the goal of your treatment is.
Can I compare my outcome to someone I have read about or spoken to?
Patient stories are valuable for emotional support and for understanding what to expect day to day. Comparing outcomes is less useful and often misleading, because two people with the same cancer type can have tumours with very different biology, different prior treatments, and different overall health — all of which affect response. The person who responded for years and the person who progressed sooner were both in the same trial. Only your own results, interpreted by your oncologist, tell you where you are likely to sit.
Did you know?
Enzalutamide was the first androgen receptor inhibitor to demonstrate an overall survival benefit in castration-resistant prostate cancer — a result that shifted international treatment guidelines.
That is the evidence base your oncologist is drawing on when they recommend it.
Source: AFFIRM trial results, cited in NCCN Guidelines for Prostate Cancer and ESMO Clinical Practice Guidelines
Explore 50 more Prostate Cancer Targeted Medicines topics
Drug Deep Dive: Enzalutamide (Xtandi)
- Diet and Nutrition While on Enzalutamide
- Dizziness, Falls and Seizure Risk on Enzalutamide
- Does Enzalutamide Need a Steroid? Why It Differs From Abiraterone
- Enzalutamide (Xtandi, Bdenza, Enzamide): The Complete Patient Guide
- Enzalutamide Interactions: Blood Thinners, Statins and Seizure-Threshold Drugs
- Enzalutamide Myths: 'It's Chemotherapy', Fatigue and Loss of Masculinity
- Enzalutamide Price in India: Brand, Generic and Monthly Cost
- Enzalutamide Side Effects: The Complete List and Timeline
- Enzalutamide Success Rate and Survival: An Honest Look at the Numbers
- Enzalutamide With ADT and Other Prostate Cancer Treatments
- Enzalutamide in Elderly Patients and Those With Other Illnesses
- Enzalutamide in Non-Metastatic vs Metastatic Prostate Cancer
- Enzalutamide vs Abiraterone vs Apalutamide: Choosing an AR Inhibitor
- Fertility, Pregnancy and Contraception on Enzalutamide
- How Does Enzalutamide Work? The Androgen Receptor Signalling Inhibitor Explained
- How Long Does Enzalutamide Take to Work?
- How Long Will You Stay on Enzalutamide?
- Memory, Concentration and Blood Pressure Changes on Enzalutamide
- Severe Fatigue on Enzalutamide: The Commonest Reason Men Stop
- Taking Enzalutamide: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Enzalutamide
- When Enzalutamide Stops Working: Resistance and What Comes Next
- Who Is Eligible for Enzalutamide? Advanced and Metastatic Prostate Cancer
- Will Insurance or a Government Scheme Pay for Enzalutamide?
- Work, Travel and Daily Life on Enzalutamide
Drug Deep Dive: Abiraterone (Zytiga)
- Abiraterone (Zytiga, Abirapro, Abretone): The Complete Patient Guide
- Abiraterone Interactions: Steroids, BP Medicines and Herbal Products
- Abiraterone Myths: Steroids, Weight Gain and 'It Stops Working Fast'
- Abiraterone Price in India: Brand, Generic and Monthly Cost
- Abiraterone Side Effects: The Complete List and Timeline
- Abiraterone Success Rate and Survival: An Honest Look at the Numbers
- Abiraterone With ADT, Docetaxel and Radiation: Your Full Regimen Explained
- Abiraterone in Elderly Patients and Those With Other Illnesses
- Abiraterone in Hormone-Sensitive vs Castration-Resistant Prostate Cancer
- Abiraterone vs Enzalutamide: How to Choose in Prostate Cancer
- Diet and Nutrition While on Abiraterone
- Fatigue, Hot Flushes and Joint Pain on Abiraterone
- Fertility, Pregnancy and Contraception on Abiraterone
- How Does Abiraterone Work? The CYP17 Inhibitor Explained
- How Long Does Abiraterone Take to Work?
- How Long Will You Stay on Abiraterone?
- Liver Enzyme Rises on Abiraterone: Why the First Three Months Matter Most
- Swelling, Low Potassium and High Blood Pressure on Abiraterone
- Tests and Monitoring While You Are on Abiraterone
- When Abiraterone Stops Working: Resistance and What Comes Next
- Who Is Eligible for Abiraterone? Advanced and Metastatic Prostate Cancer
- Why Abiraterone Is Always Given With Prednisolone
- Why Abiraterone Must Be Taken on an Empty Stomach
- Will Insurance or a Government Scheme Pay for Abiraterone?
- Work, Travel and Daily Life on Abiraterone
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What is the success rate of enzalutamide?
There is no single success rate — it depends on what you are measuring and at which stage of prostate cancer. In the AFFIRM trial, enzalutamide showed an overall survival benefit for castration-resistant disease after chemotherapy. In PREVAIL, it extended the time before cancer progressed on scans in patients who had not yet had chemotherapy. In PROSPER, it delayed the spread of non-metastatic disease. Each of these is a different kind of success, and which one applies to you depends on your specific situation. Your oncologist can explain which trial most closely matches your case.
How will I know if enzalutamide is working for me?
The main indicators your oncologist watches are PSA trend, scan results, and your symptoms. A falling PSA is typically the first signal that the drug is working. Scans at regular intervals confirm whether the cancer is stable or growing. If you feel broadly the same or better and your PSA is coming down, those are all encouraging signals. Ask your oncologist which specific markers they are tracking and what a meaningful response would look like at your first review appointment.
What are the chances enzalutamide will work for me personally?
No one can give you a precise personal probability from trial data. Trials tell us what happened across groups of hundreds of patients, not what will happen for one individual. What we do know is that NCCN and ESMO recommend enzalutamide because a meaningful proportion of patients in the trials benefited significantly. Your oncologist can describe the range of outcomes and tell you whether anything about your case — your PSA doubling time, your prior treatment history, your Gleason score — makes response more or less likely.
What happens when enzalutamide stops working?
When enzalutamide stops controlling the cancer, there are further lines of treatment, and your oncologist will already be thinking about what comes next. The options depend on what you have already had, your overall fitness, and what evidence is available for your specific situation. Treatment sequencing for prostate cancer has expanded considerably in recent years, and progression on one treatment does not mean there are no further options. Ask your oncologist what the plan looks like beyond enzalutamide so you are not facing that conversation for the first time when it becomes urgent.
Should I look up survival statistics online?
Survival statistics published online are almost always from older data, often covering a broader or different population than your specific situation. A general survival figure for prostate cancer includes people at very different stages and in very different circumstances. The figures most relevant to you are the trial outcomes for your specific setting, interpreted by your oncologist in light of your own PSA results and scans. If you read something online that worries you, bring it to your next appointment and ask whether it applies to your case.
Is enzalutamide available at CION?
Yes. Enzalutamide is given as day care at CION centres, which means no overnight stay is needed for each treatment. Your oncologist will coordinate regular PSA monitoring and response-assessment imaging — typically PET-CT scans organised through partner imaging centres — as part of your ongoing review. If you want to understand what your visits will look like in practice, ask your care coordinator at your next appointment.